Company intelligence / Profile preview

Viz.ai

San Francisco, California, United Statesviz.com ↗

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

The Viz.ai One™ platform has demonstrated significant improvements in time-to-diagnosis and patient outcomes across neurovascular and cardiovascular pathways. Over one hundred peer-reviewed publications support its efficacy. Increases access to life-saving treatments by reducing systemic delays between diagnosis and intervention.

Therapeutic areas: CardiovascularNeurology
Modalities: DeviceNon-pharmacological therapySoftware/AI algorithm
Industry: Medical Imaging

Partnerships

Ten partnerships with leading global pharmaceutical companies as of January 2025; specific names not all disclosed publicly.Bristol Myers Squibb for hypertrophic cardiomyopathy module development.

Beyond the preview

Go deeper on Viz.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viz.ai.

Explore the full profile